Should I Buy IOBT? IOBT 2026 Analysis

Should You Buy IO Biotech Inc (IOBT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.350

1 Day change

9.37%

52 Week Range

2.790

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: the stock is in a clear bearish trend with no proprietary buy signals and no near-term catalysts.
Fundamentals and Street narrative are dominated by the Phase 3 failure/FDA recommendation against filing, which keeps upside speculative and timing uncertain.
Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.
If you already hold shares, the current setup favors exiting/avoiding rather than trying to “catch the bottom.”

Technical Analysis

Trend: Bearish structure with SMA_200 > SMA_20 > SMA_5 (persistent downtrend).
Momentum: MACD histogram -0.00607 (below zero) and still negative → downside momentum remains.
RSI: RSI_6 = 32.7 (near-oversold but not a reversal signal by itself).
Key levels: Price (~0.272) is above S1 0.244 but well below pivot 0.377 and resistance (R1 0.511). A break below 0.244 opens risk toward S2 0.162.
Pattern-based projection (low edge): Similar-pattern stats suggest only modest near-term upside (next week +2.16%) but negative 1-month expectation (-0.96%).

Positive Catalysts

- Potential strategic alternatives process (exploring options to maximize shareholder value) could create event-driven upside if a favorable deal emerges.
- “Oversold-ish” technical condition (RSI low 30s) can support short-lived rebounds if broader risk-on sentiment appears.

Neutral/Negative Catalysts

- Major clinical/regulatory setback: Phase 3 melanoma study for lead program failed and FDA recommended against regulatory filing (overhang likely persists).
- Analyst downgrades and sharp price target cuts signal reduced institutional confidence and limited near-term support.
- Ongoing capital constraints highlighted by analysts increase dilution/financing risk.
- No supportive near-term news flow reported in the past week.

Financial Performance

Latest quarter: 2025/Q3
Revenue: 0 (no meaningful operating revenue base).
Net income: -8.378M, deteriorated -65.11% YoY (losses widened).
EPS: -0.13, worsened -63.89% YoY.
Overall: financial trend reflects a cash-consuming biotech profile with worsening losses, which is particularly problematic alongside trial failure and capital constraints.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: clear downgrade cycle with steep target cuts.
Piper Sandler (2026-01-23/26): Downgraded to Neutral from Overweight; PT cut to $0.50 from $3, citing strategic alternatives uncertainty and capital constraints.
Morgan Stanley (2026-01-08): Downgraded to Underweight; PT $0.36 (from $0.39) after Phase 3 failure and FDA stance.
Wall Street pros vs cons:
- Pros: platform science still viewed as “promising” conceptually.
- Cons (dominant): lead-program failure, delayed/uncertain path to value creation, funding constraints, and no assurance strategic process yields an attractive transaction.

3 Analyst Rating

Wall Street analysts forecast IOBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOBT is 1.68 USD with a low forecast of 0.36 USD and a high forecast of 3 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

1 Sell

Hold

Current: 0.320

Low

0.36

Averages

1.68

High

Current: 0.320

Low

0.36

Averages

1.68

High

Piper Sandler

Overweight -> Neutral

downgrade

AI Analysis

2026-01-26

Reason

Piper Sandler

Price Target

AI Analysis

2026-01-26

downgrade

Overweight -> Neutral

Reason

Piper Sandler Friday night downgraded IO Biotech to Neutral from Overweight with a price target of 50c, down from $3. The firm cites the company's intention to explore strategic opportunities to maximize shareholder value for the downgrade. While the underlying science behind IO's T-win platform and lead candidate cylembio is promising, the company continues to face capital constraints, the analyst tells investors in a research note. Piper stepped to the sidelines, saying there's no assurance the company's strategic alternatives process will pan out favorably, or that a transaction will be completed on attractive terms.

Piper Sandler

Allison Bratzel

Overweight

Neutral

downgrade

2026-01-23

Reason

Piper Sandler

Allison Bratzel

Price Target

2026-01-23

downgrade

Overweight

Neutral

Reason

Piper Sandler analyst Allison Bratzel downgraded IO Biotech to Neutral from Overweight with a price target of 50c, down from $3.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IOBT

Unlock Now

IOBT Should I Buy

IOBT Should I Buy

Should You Buy IO Biotech Inc (IOBT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch